【无锡/上海】近日，无锡途深智合人工智能科技有限公司及其上海子公司——上海途深生物科技有限责任公司（简称「途深智合」）成功完成了数百万元的天使轮融资，投资方为诚美资本。这一轮融资将主要用于实验室的建设和专业团队的建设，以推动公司在人工智能蛋白质设计与优化领域的深度研发。
「途深智合」成立于2023年，是一家专注于利用人工智能技术进行蛋白质设计和制造的生物科技新秀。公司致力于为合成生物领域提供创新的解决方案和新产品，以满足行业对高效、精准蛋白质设计的需求。通过将人工智能与生物技术相结合，「途深智合」有望打破传统蛋白质工程的局限，加速合成生物学的发展，为医药、环保、能源等多个行业带来变革。
诚美资本的投资彰显了市场对「途深智合」技术实力和未来前景的认可。随着资金的注入，「途深智合」将加速实验室的建设和人才队伍的扩充，以期在生物科技和人工智能的交叉领域中实现更多突破，为全球生物科技产业带来新的增长点。
「途深智合」的创始人表示，他们期待通过本次融资，能够进一步提升公司的技术研发能力，为合成生物领域带来更具创新性的产品和服务，推动行业科技进步。同时，他们也将积极探索与产业上下游的合作，共同构建一个更加智能、高效的生物技术生态系统。
此次融资事件标志着「途深智合」在人工智能蛋白质设计领域的崭新起点，预示着公司在生物科技创新道路上的坚定步伐。随着科研成果的不断转化，我们有望看到更多由「途深智合」引领的科技成果转化应用，为人类社会带来福祉。
英语如下：
**News Title:** “TuShen ZhiHe Secures Angel Round Investment in Millions, Accelerating AI Protein Design Innovation”
**Keywords:** AI Protein Design, TuShen ZhiHe, Angel Financing Round
**News Content:** **Wuxi/Shanghai** – Recently, Wuxi TuShen ZhiHe Artificial Intelligence Technology Co., Ltd. and its Shanghai subsidiary, Shanghai TuShen Biological Technology Co., Ltd. (collectively known as “TuShen ZhiHe”), successfully completed an angel financing round in the millions of yuan, backed by Chengmei Capital. This funding will primarily support laboratory construction and the development of a professional team to advance the company’s in-depth research and development in AI protein design and optimization.
TuShen ZhiHe, founded in 2023, is a biotech startup specializing in AI-driven protein design and manufacturing. The company aims to provide innovative solutions and new products to the synthetic biology sector, catering to the demand for efficient and precise protein design. By integrating AI with biotechnology, TuShen ZhiHe aspires to overcome the limitations of traditional protein engineering, accelerating the progression of synthetic biology and bringing transformation to industries such as pharmaceuticals, environmental protection, and energy.
Chengmei Capital’s investment underscores the market’s recognition of TuShen ZhiHe’s technical capabilities and promising future prospects. With the influx of capital, the company will expedite laboratory development and team expansion, striving for breakthroughs in the intersection of biotechnology and AI, thereby contributing new growth drivers to the global biotech industry.
The founder of TuShen ZhiHe expressed their anticipation that this financing round will boost the company’s R&D capabilities, enabling the introduction of more innovative products and services to the synthetic biology field and propelling technological progress. They also plan to actively explore collaborations with industry partners upstream and downstream, jointly building a smarter and more efficient biotechnology ecosystem.
This financing milestone signals a new beginning for TuShen ZhiHe in the realm of AI protein design, signifying the company’s steadfast strides in the innovation-driven path of biotechnology. As research outcomes continue to be translated into practical applications, we can expect to witness more technology conversions led by TuShen ZhiHe, benefiting humanity at large.
【来源】https://36kr.com/p/2686282258132355
Views: 7